Asian Journal of Surgery (Sep 2019)

Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience

  • Jing-jing Wu,
  • Zhan-guo Zhang,
  • Peng Zhu,
  • Abdoul-aziz Mba'nbo-koumpa,
  • Bi-xiang Zhang,
  • Xiao-ping Chen,
  • Chang Shu,
  • Wan-guang Zhang,
  • Ren-jie Feng,
  • Gan-xun Li

Journal volume & issue
Vol. 42, no. 9
pp. 874 – 882

Abstract

Read online

Summary: Background/Objective: Previous studies have proposed several objective means for liver function assessment in hepatocellular carcinoma (HCC) patients; however, their efficiency in predicting survival of HCC rupture is unknown. Our study aims to confirm which is a better liver function model for ruptured HCC. Methods: A total of 230 patients with HCC ruptures at our center were included. Kaplan–Meier and Cox regression analyses were performed to compare long-term survival and short-term mortality. The 90-day mortality was compared with the area under the receiver characteristic curve. Logistic regression was used to determine the risk factors for 90-day deaths, and the discriminant ability of the model was measured. Results: There were significant differences in predicting OS of the Child-Pugh (CP) score in all patients, the non-surgical subgroup, and the surgical subgroup (all P < 0.0001). But no statistical significance was shown of the ALBI score in the surgical (P = 0.8985) or non-surgical subgroup (P = 0.0634). The CP score yielded a better performance among all patients (AUC = 0.746 vs. 0.712), the surgical subgroup (AUC = 0.558 vs. 0.530), and the non-surgical subgroup (AUC = 0.715 vs. 0.634) compared to ALBI score in predicting ninety-day mortality. A similar result can be found in the subgroup of surgical and non-surgical treatment group. Moreover, the logistic model that included CP or MELD had a better discriminatory ability than ALBI in predicting ninety-day mortality. Conclusion: The CP or MELD rather than ALBI score should be used as a liver function classification criterion for HCC rupture. Clinical trial number: NCT03534843 (retrospectively). Keywords: Albumin, Bilirubin, Survival, Rupture, Liver function, Model